IBRX missed EPS expectations by 14.85%
May 15, 2025, 10:36 PM
0.00%
What does IBRX do
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
ImmunityBio (IBRX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, ImmunityBio's actual EPS was -$0.15, missing the estimate of -$0.13 per share, resulting in a -14.85% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.